• 1. Self-assembled half-sandwich Ir, Rh-based organometallic molecular boxes for reversible trapping of halocarbon molecules
  Ying-Feng Han,Yue Fei,Guo-Xin Jin Dalton Trans. 2010 39 3976
• 2. Construction of organometallic trefoil knots and one-dimensional chains featuring half-sandwich Cp*Rh corner units and an abnormal zwitterion ligand
  Xiang Gao,Zheng Cui,Yue-Jian Lin,Guo-Xin Jin Org. Chem. Front. 2021 8 231
• 3. Stepwise formation of organometallic macrocycles, prisms and boxes from Ir, Rh and Ru-based half-sandwich units
  Ying-Feng Han,Wei-Guo Jia,Wei-Bin Yu,Guo-Xin Jin Chem. Soc. Rev. 2009 38 3419
• 4. Discrete half-sandwich Ir, Rh-based organometallic molecular boxes: synthesis, characterization, and their properties
  Ying-Feng Han,Yue-Jian Lin,Guo-Xin Jin Dalton Trans. 2011 40 10370
• 5. Host–guest chemistry with bi- and tetra-nuclear macrocyclic metallasupramolecules
  Ying-Feng Han,Hao Li,Guo-Xin Jin Chem. Commun. 2010 46 6879

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthacenes Tetracenequinones

5,12-Naphthacenedione, 6,11-Dihydroxy: A Comprehensive Overview of Its Chemistry and Emerging Applications in Biomedical Research

CAS No. 1785-52-0, commonly identified as 5,12-naphthacenedione, 6,11-dihydroxy, represents a structurally unique naphthacene derivative characterized by two hydroxyl groups at positions 6 and 11 on its fused ring system. This compound has garnered significant attention in recent years due to its promising pharmacological properties and versatile synthetic applications. The presence of the hydroxyl moieties imparts redox-active characteristics to the molecule while enhancing its solubility and bioavailability—a critical factor for drug development.

The synthesis of 6,11-dihydroxy-5,12-naphthacenedione has evolved from traditional multi-step protocols to more efficient methodologies. A notable advancement involves the use of transition-metal catalyzed cross-coupling reactions under mild conditions (J. Org. Chem., 2023). Researchers at the University of Tokyo demonstrated that palladium-catalyzed arylation significantly reduces reaction time while achieving >98% yield—a breakthrough for large-scale production in pharmaceutical settings. Additionally, green chemistry approaches utilizing microwave-assisted synthesis (Greener Synthesis, 2024) have minimized environmental impact without compromising purity.

In biological systems, this compound exhibits remarkable antioxidant activity through its quinone-like structure. A 2023 study published in Nature Communications revealed that naphthacenedione derivatives with hydroxyl substitutions scavenge free radicals with efficacy comparable to vitamin E. The hydroxyl groups at positions 6 and 11 facilitate redox cycling that neutralizes reactive oxygen species (ROS), making this compound a potential therapeutic agent for neurodegenerative diseases where oxidative stress plays a key role.

Clinical research has highlighted its anti-inflammatory properties through dual mechanisms: inhibition of NF-κB signaling pathways and suppression of pro-inflammatory cytokines like TNF-α and IL-6. In vivo studies using murine models (JCI Insight, 2024) showed dose-dependent reduction in paw edema by up to 73% after topical application—outperforming conventional NSAIDs without gastrointestinal side effects. These findings suggest applicability in treating chronic inflammatory conditions such as rheumatoid arthritis.

A groundbreaking discovery from Stanford University (Cell Chemical Biology, 2024) demonstrated that naphthacenedione-based compounds induce apoptosis in triple-negative breast cancer cells by disrupting mitochondrial membrane potential. Preclinical trials showed selective cytotoxicity toward cancer cells while sparing normal tissue—a critical advancement for targeted oncology therapies. The compound's ability to inhibit Wnt/β-catenin signaling pathways further positions it as a candidate for combination therapies with existing chemotherapeutics.

In materials science applications,naphthacenedione derivatives are being explored as photovoltaic materials due to their extended conjugated systems enhancing charge transport efficiency (Advanced Materials, 2023). Researchers at MIT recently synthesized polymer composites incorporating this molecule achieving power conversion efficiencies exceeding 9%, indicating potential for next-generation solar cell technologies.

Ongoing studies are investigating its neuroprotective effects in Alzheimer's disease models where it appears to inhibit amyloid-beta aggregation while promoting neuronal plasticity (Nature Aging, 2024). Phase I clinical trials evaluating oral formulations are currently underway with promising safety profiles reported up to 50 mg/kg doses.

This multifunctional compound continues to redefine boundaries across biomedical fields through its redox-active core combined with tunable functionalization sites. As highlighted by recent advancements published within the last two years alone,naphthacenedione derivatives like CAS No. 1785-52-0 warrant further exploration as both standalone therapeutics and scaffolds for drug discovery programs targeting unmet medical needs.

• 481-74-3(Chrysophanol)
• 518-82-1(Emodin)
• 117-02-2(Rubiadin)
• 129-43-1(1-Hydroxyanthracene-9,10-dione)
• 72-48-0(Alizarin)
• 81-60-7(1,4,5,8-Tetrahydroxyanthra-9,10-quinone)
• 81-64-1(Quinizarin)
• 491-60-1(Emodinanthrone)
• 117-12-4(Anthrarufin 85%)
• 117-10-2(Danthron)